Mustang Historical Balance Sheet

MBIO Stock

USD 0.20 0.01 4.76%

Trend analysis of Mustang Bio balance sheet accounts such as Total Stockholder Equity of 116.8 K provides information on Mustang Bio's total assets, liabilities, and equity, which is the actual value of Mustang Bio to its prevalent stockholders. By breaking down trends over time using Mustang Bio balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Mustang Bio latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Mustang Bio is a good buy for the upcoming year.

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mustang Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in Mustang Stock, please use our How to Invest in Mustang Bio guide.

About Mustang Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Mustang Bio at a specified time, usually calculated after every quarter, six months, or one year. Mustang Bio Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Mustang Bio and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Mustang currently owns. An asset can also be divided into two categories, current and non-current.

Mustang Bio Balance Sheet Chart

At this time, Mustang Bio's Long Term Debt is very stable compared to the past year. As of the 26th of November 2024, Other Liabilities is likely to grow to about 366 K, while Short and Long Term Debt Total is likely to drop about 2.4 M.

Other Current Liab Total Current Liabilities Total Stockholder Equity Accounts Payable Common Stock Total Equity Total Liab

Add Fundamental

Total Current Liabilities

Total Current Liabilities is an item on Mustang Bio balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Mustang Bio are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Accounts Payable

An accounting item on the balance sheet that represents Mustang Bio obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Mustang Bio are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Common Stock Total Equity

The total value of common stock equity held by shareholders, representing their ownership interest in the company.

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Most accounts from Mustang Bio's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Mustang Bio current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mustang Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in Mustang Stock, please use our How to Invest in Mustang Bio guide.At this time, Mustang Bio's Long Term Debt is very stable compared to the past year. As of the 26th of November 2024, Other Liabilities is likely to grow to about 366 K, while Short and Long Term Debt Total is likely to drop about 2.4 M.

	2021	2022	2023	2024 (projected)
Other Current Liabilities	6.6M	7.1M	8.0M	4.1M
Short and Long Term Debt Total	2.0M	31.4M	2.5M	2.4M

Other Current Liab Short Long Term Debt Total

Mustang Bio balance sheet Correlations

	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Other Stockholder Equity	Total Liab	Short Long Term Debt	Short Term Debt	Common Stock	Total Assets	Current Deferred Revenue	Cash	Cash And Short Term Investments	Retained Earnings Total Equity	Total Current Assets	Other Liab	Property Plant And Equipment Net	Net Receivables
Short Long Term Debt Total		0.18	0.34	0.25	0.23	-0.16	-0.23	0.57	0.18	-0.33	0.79	0.23	0.33	0.72	-0.3	-0.19	0.56	0.37	-0.37	0.22	0.32	-0.29	0.33	0.34	0.44	-0.2
Other Current Liab	0.18		0.96	0.48	0.87	-0.58	-0.91	0.71	0.9	-0.21	0.41	0.9	0.95	0.74	-0.59	-0.67	0.64	0.53	0.04	0.5	0.41	-0.92	0.46	0.36	0.78	0.48
Total Current Liabilities	0.34	0.96		0.36	0.86	-0.43	-0.93	0.81	0.88	-0.14	0.51	0.88	0.95	0.82	-0.51	-0.57	0.61	0.44	0.03	0.37	0.31	-0.9	0.36	0.47	0.77	0.52
Total Stockholder Equity	0.25	0.48	0.36		0.53	-0.98	-0.32	0.46	0.5	-0.65	0.11	0.53	0.6	0.29	-0.62	-0.68	0.81	0.95	-0.56	0.87	0.93	-0.63	0.94	0.33	0.69	-0.29
Net Tangible Assets	0.23	0.87	0.86	0.53		-0.56	-0.96	0.84	0.99	-0.47	0.23	0.99	0.94	0.64	-0.74	-0.81	0.56	0.48	-0.16	0.35	0.35	-0.94	0.41	0.53	0.79	0.62
Net Debt	-0.16	-0.58	-0.43	-0.98	-0.56		0.39	-0.41	-0.56	0.57	-0.14	-0.58	-0.65	-0.34	0.6	0.69	-0.83	-0.95	0.43	-0.91	-0.93	0.69	-0.94	-0.27	-0.72	0.24
Retained Earnings	-0.23	-0.91	-0.93	-0.32	-0.96	0.39		-0.82	-0.97	0.26	-0.34	-0.96	-0.93	-0.73	0.6	0.67	-0.49	-0.33	-0.02	-0.23	-0.19	0.91	-0.25	-0.52	-0.77	-0.72
Accounts Payable	0.57	0.71	0.81	0.46	0.84	-0.41	-0.82		0.82	-0.53	0.37	0.84	0.86	0.69	-0.73	-0.72	0.57	0.41	-0.36	0.21	0.29	-0.81	0.33	0.75	0.72	0.44
Common Stock Total Equity	0.18	0.9	0.88	0.5	0.99	-0.56	-0.97	0.82		-0.41	0.24	1.0	0.95	0.65	-0.7	-0.78	0.56	0.47	-0.14	0.37	0.35	-0.96	0.4	0.55	0.82	0.63
Common Stock Shares Outstanding	-0.33	-0.21	-0.14	-0.65	-0.47	0.57	0.26	-0.53	-0.41		0.01	-0.44	-0.38	-0.18	0.88	0.83	-0.38	-0.44	0.73	-0.27	-0.4	0.41	-0.41	-0.52	-0.45	0.01
Non Current Liabilities Total	0.79	0.41	0.51	0.11	0.23	-0.14	-0.34	0.37	0.24	0.01		0.26	0.38	0.89	-0.13	-0.09	0.61	0.34	0.06	0.35	0.29	-0.36	0.3	0.07	0.5	-0.12
Capital Surpluse	0.23	0.9	0.88	0.53	0.99	-0.58	-0.96	0.84	1.0	-0.44	0.26		0.95	0.67	-0.71	-0.78	0.57	0.5	-0.2	0.39	0.37	-0.97	0.42	0.58	0.84	0.6
Other Stockholder Equity	0.33	0.95	0.95	0.6	0.94	-0.65	-0.93	0.86	0.95	-0.38	0.38	0.95		0.74	-0.7	-0.76	0.71	0.61	-0.15	0.51	0.5	-0.97	0.54	0.53	0.85	0.45
Total Liab	0.72	0.74	0.82	0.29	0.64	-0.34	-0.73	0.69	0.65	-0.18	0.89	0.67	0.74		-0.43	-0.43	0.71	0.45	-0.01	0.4	0.35	-0.73	0.38	0.35	0.76	0.23
Short Long Term Debt	-0.3	-0.59	-0.51	-0.62	-0.74	0.6	0.6	-0.73	-0.7	0.88	-0.13	-0.71	-0.7	-0.43		0.98	-0.5	-0.45	0.45	-0.29	-0.37	0.66	-0.4	-0.54	-0.61	-0.28
Short Term Debt	-0.19	-0.67	-0.57	-0.68	-0.81	0.69	0.67	-0.72	-0.78	0.83	-0.09	-0.78	-0.76	-0.43	0.98		-0.55	-0.52	0.39	-0.39	-0.44	0.74	-0.47	-0.53	-0.67	-0.31
Common Stock	0.56	0.64	0.61	0.81	0.56	-0.83	-0.49	0.57	0.56	-0.38	0.61	0.57	0.71	0.71	-0.5	-0.55		0.91	-0.23	0.87	0.87	-0.71	0.89	0.31	0.82	-0.25
Total Assets	0.37	0.53	0.44	0.95	0.48	-0.95	-0.33	0.41	0.47	-0.44	0.34	0.5	0.61	0.45	-0.45	-0.52	0.91		-0.43	0.96	0.99	-0.65	0.99	0.23	0.74	-0.37
Current Deferred Revenue	-0.37	0.04	0.03	-0.56	-0.16	0.43	-0.02	-0.36	-0.14	0.73	0.06	-0.2	-0.15	-0.01	0.45	0.39	-0.23	-0.43		-0.26	-0.42	0.24	-0.42	-0.46	-0.26	0.25
Cash	0.22	0.5	0.37	0.87	0.35	-0.91	-0.23	0.21	0.37	-0.27	0.35	0.39	0.51	0.4	-0.29	-0.39	0.87	0.96	-0.26		0.97	-0.56	0.97	0.05	0.66	-0.44
Cash And Short Term Investments	0.32	0.41	0.31	0.93	0.35	-0.93	-0.19	0.29	0.35	-0.4	0.29	0.37	0.5	0.35	-0.37	-0.44	0.87	0.99	-0.42	0.97		-0.53	1.0	0.12	0.63	-0.48
Retained Earnings Total Equity	-0.29	-0.92	-0.9	-0.63	-0.94	0.69	0.91	-0.81	-0.96	0.41	-0.36	-0.97	-0.97	-0.73	0.66	0.74	-0.71	-0.65	0.24	-0.56	-0.53		-0.58	-0.58	-0.92	-0.43
Total Current Assets	0.33	0.46	0.36	0.94	0.41	-0.94	-0.25	0.33	0.4	-0.41	0.3	0.42	0.54	0.38	-0.4	-0.47	0.89	0.99	-0.42	0.97	1.0	-0.58		0.16	0.67	-0.43
Other Liab	0.34	0.36	0.47	0.33	0.53	-0.27	-0.52	0.75	0.55	-0.52	0.07	0.58	0.53	0.35	-0.54	-0.53	0.31	0.23	-0.46	0.05	0.12	-0.58	0.16		0.64	0.29
Property Plant And Equipment Net	0.44	0.78	0.77	0.69	0.79	-0.72	-0.77	0.72	0.82	-0.45	0.5	0.84	0.85	0.76	-0.61	-0.67	0.82	0.74	-0.26	0.66	0.63	-0.92	0.67	0.64		0.18
Net Receivables	-0.2	0.48	0.52	-0.29	0.62	0.24	-0.72	0.44	0.63	0.01	-0.12	0.6	0.45	0.23	-0.28	-0.31	-0.25	-0.37	0.25	-0.44	-0.48	-0.43	-0.43	0.29	0.18

Click cells to compare fundamentals

Mustang Bio Account Relationship Matchups

Mustang Bio balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Other Current Liab	3.8M	5.4M	6.6M	7.1M	8.0M	4.1M
Total Current Liabilities	7.8M	9.5M	10.8M	15.1M	15.4M	9.2M
Total Stockholder Equity	51.7M	98.4M	112.4M	46.3M	123K	116.9K
Net Tangible Assets	36.4M	51.7M	98.4M	112.4M	129.3M	135.7M
Net Debt	(45.9M)	(95.6M)	(107.6M)	(44.3M)	(3.7M)	(3.9M)
Retained Earnings	(125.5M)	(185.5M)	(251.8M)	(329.4M)	(381.0M)	(361.9M)
Accounts Payable	2.5M	3.5M	3.5M	6.8M	6.3M	4.0M
Common Stock Shares Outstanding	2.4M	3.5M	5.9M	6.9M	8.6M	5.3M
Non Current Liabilities Total	14.0M	2.0M	2.0M	31.0M	2.2M	2.1M
Capital Surpluse	98.7M	113.4M	172.2M	276.0M	317.4M	333.2M
Other Stockholder Equity	172.2M	276.0M	359.9M	374.5M	380.5M	223.5M
Total Liab	21.8M	11.5M	12.8M	46.1M	17.6M	15.5M
Total Assets	73.4M	109.9M	125.2M	92.4M	17.7M	16.9M
Cash	61.4M	97.8M	109.6M	75.7M	6.2M	5.9M
Non Current Assets Total	10.4M	10.4M	13.5M	13.6M	6.4M	8.8M
Other Assets	771K	1.3M	2.8M	1.4M	1.6M	1.3M
Cash And Short Term Investments	61.4M	97.8M	109.6M	75.7M	6.2M	5.9M
Retained Earnings Total Equity	(48.4M)	(79.1M)	(125.5M)	(185.5M)	(166.9M)	(158.6M)
Liabilities And Stockholders Equity	73.4M	109.9M	125.2M	92.4M	17.7M	16.9M
Total Current Assets	63.1M	99.5M	111.7M	78.9M	11.3M	10.8M
Accumulated Other Comprehensive Income	4.9M	7.9M	4.3M	1.1M	591K	561.5K
Property Plant Equipment	9.1M	9.1M	12.1M	12.3M	14.2M	8.0M
Property Plant And Equipment Net	9.1M	9.1M	12.1M	12.3M	4.8M	8.8M
Net Receivables	19K	15K	50K	299K	3.9M	4.1M
Other Current Assets	1.6M	1.7M	2.0M	3.2M	1.2M	1.7M
Net Invested Capital	65.1M	98.4M	112.4M	73.7M	123K	116.9K
Property Plant And Equipment Gross	9.1M	9.1M	12.1M	12.3M	9.3M	9.5M
Net Working Capital	55.3M	90.0M	100.9M	63.7M	(4.0M)	(3.8M)
Capital Stock	4K	7K	9K	11K	1K	950.0

Pair Trading with Mustang Bio

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mustang Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mustang Bio will appreciate offsetting losses from the drop in the long position's value.

Moving together with Mustang Stock

0.69

VALN

Valneva SE ADR

Pair Corr

Moving against Mustang Stock

0.37

RNXT

RenovoRx

Pair Corr

The ability to find closely correlated positions to Mustang Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mustang Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mustang Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mustang Bio to buy it.

The correlation of Mustang Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mustang Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mustang Bio moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Mustang Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Mustang Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mustang Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mustang Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mustang Bio Stock:

How To Invest In Mustang

Details

Is Mustang Stock a good investment?

Details

What is Mustang Bio's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in Mustang Stock, please use our How to Invest in Mustang Bio guide.

You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mustang Bio. If investors know Mustang will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mustang Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.33)

Revenue Per Share

(0)

Return On Assets

(0.97)

Return On Equity

(11.91)

The market value of Mustang Bio is measured differently than its book value, which is the value of Mustang that is recorded on the company's balance sheet. Investors also form their own opinion of Mustang Bio's value that differs from its market value or its book value, called intrinsic value, which is Mustang Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mustang Bio's market value can be influenced by many factors that don't directly affect Mustang Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Mustang Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mustang Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mustang Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Mustang Historical Balance Sheet

About Mustang Balance Sheet Analysis

Mustang Bio Balance Sheet Chart

Total Current Liabilities

Total Stockholder Equity

Accounts Payable

Common Stock Total Equity

Total Liab

Mustang Bio balance sheet Correlations

Mustang Bio Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Mustang Bio balance sheet Accounts

Pair Trading with Mustang Bio

Moving together with Mustang Stock

Moving against Mustang Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Capital Surpluse	+ 1.0	Common Stock Total Equity
Total Current Assets	+ 1.0	Cash And Short Term Investments
Common Stock Total Equity	+ 0.99	Net Tangible Assets
Capital Surpluse	+ 0.99	Net Tangible Assets
Cash And Short Term Investments	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Assets

Net Debt	- 0.98	Total Stockholder Equity
Retained Earnings Total Equity	- 0.97	Other Stockholder Equity
Retained Earnings Total Equity	- 0.97	Capital Surpluse
Common Stock Total Equity	- 0.97	Retained Earnings
Retained Earnings Total Equity	- 0.96	Common Stock Total Equity
Capital Surpluse	- 0.96	Retained Earnings